open access

Vol 6, No 1 (2001)
Untitled
Published online: 2001-01-01
Submitted:
Get Citation

87. High dose rate endobronchial brachytherapy in the management of advanced bronchial cancer – comparison of different doses

J. Skowronek, K. Adamska, G. Zwierzchowski, S. Cofta, K. Świerkocki, T. Piorunek, W. Młynarczyk
DOI: 10.1016/S1507-1367(01)70457-9
·
Rep Pract Oncol Radiother 2001;6(1):67.

open access

Vol 6, No 1 (2001)
Untitled
Published online: 2001-01-01
Submitted:

Abstract

Introduction

In palliative treatment of lung cancer one of most efficient methods in overcoming difficulties in breathing caused by endobronchial obstruction is brachytherapy. From regard on location of the change on some of the patients brachytherapy is a treatment from choice. Brachytherapy in single cases is performed as radical treatment, in most of cases due to advanced clinical stage has an palliative aim. Because of lack of clear consensus regarding value of doses used in brachytherapy there are different fraction doses used in clinical treatment. The work is about result (t of palliative treatment with high dose rate brachytherapy using different treatment schemas.

Material and methods

From May 1999 to February 2000 in Greatpoland Cancer Centre were treated 69 patients on bronchial cancer using high dose rate brachytherapy. They were disqualified from radical treatment due to advanced clinical stage. The age of the patients ranged from 39 to 76 years, average 53,2 years. 51 patients received total dose of 22,5 Gy in 3 fractions every week, 18 patients received one single fraction of 10 Gy. Patients were divided into two groups according to clinical stage and Karnofsky scare for single fraction patients were qualified when Karnofsky scare was smaller then 50. They have undertaken clinical and endobronchial observation with rating of local remission and retiring difficulties with breathing, cough and hemoptysis in thirst, third, sixth and twelve month of observation.

Results

After 4 weeks from the end of the treatment in 61/69 (88,4%) patients has been ascertained subjective improvement (retiring of all symptoms). In 12 cases was found out complete remission (CR), in 49 partial remission (PR) of tumour. During one year of observation 45 patients died, in 10/24 cases we observed still an improvement of dyspnoea, in 14/24 cases we observed recurrence and progression of disease. There was no statistical difference in survival between two groups of patients treated with different schema.

Conclusions

  • 1.

    Brachytherapy in advanced lung cancer was an efficient method that caused in many patients retiring of the symptoms and improvement of life quality.

  • 2.

    Both treatment schema had similar efficiency in overcoming difficult breathing.

  • 3.

    High local dose did not influenced the growth of the frequency of complications.

Abstract

Introduction

In palliative treatment of lung cancer one of most efficient methods in overcoming difficulties in breathing caused by endobronchial obstruction is brachytherapy. From regard on location of the change on some of the patients brachytherapy is a treatment from choice. Brachytherapy in single cases is performed as radical treatment, in most of cases due to advanced clinical stage has an palliative aim. Because of lack of clear consensus regarding value of doses used in brachytherapy there are different fraction doses used in clinical treatment. The work is about result (t of palliative treatment with high dose rate brachytherapy using different treatment schemas.

Material and methods

From May 1999 to February 2000 in Greatpoland Cancer Centre were treated 69 patients on bronchial cancer using high dose rate brachytherapy. They were disqualified from radical treatment due to advanced clinical stage. The age of the patients ranged from 39 to 76 years, average 53,2 years. 51 patients received total dose of 22,5 Gy in 3 fractions every week, 18 patients received one single fraction of 10 Gy. Patients were divided into two groups according to clinical stage and Karnofsky scare for single fraction patients were qualified when Karnofsky scare was smaller then 50. They have undertaken clinical and endobronchial observation with rating of local remission and retiring difficulties with breathing, cough and hemoptysis in thirst, third, sixth and twelve month of observation.

Results

After 4 weeks from the end of the treatment in 61/69 (88,4%) patients has been ascertained subjective improvement (retiring of all symptoms). In 12 cases was found out complete remission (CR), in 49 partial remission (PR) of tumour. During one year of observation 45 patients died, in 10/24 cases we observed still an improvement of dyspnoea, in 14/24 cases we observed recurrence and progression of disease. There was no statistical difference in survival between two groups of patients treated with different schema.

Conclusions

  • 1.

    Brachytherapy in advanced lung cancer was an efficient method that caused in many patients retiring of the symptoms and improvement of life quality.

  • 2.

    Both treatment schema had similar efficiency in overcoming difficult breathing.

  • 3.

    High local dose did not influenced the growth of the frequency of complications.

Get Citation
About this article
Title

87. High dose rate endobronchial brachytherapy in the management of advanced bronchial cancer – comparison of different doses

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 6, No 1 (2001)

Pages

67

Published online

2001-01-01

DOI

10.1016/S1507-1367(01)70457-9

Bibliographic record

Rep Pract Oncol Radiother 2001;6(1):67.

Authors

J. Skowronek
K. Adamska
G. Zwierzchowski
S. Cofta
K. Świerkocki
T. Piorunek
W. Młynarczyk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl